Navigation Links
Eiger BioPharmaceuticals Appoints Paul Truex to Board of Directors

PALO ALTO, Calif., Aug. 17, 2009 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies with a focus on the NS4B Hepatitis C Virus (HCV) protein, announced today the appointment of Paul Truex to its Board of Directors.

Truex is the founder, President and CEO of Anthera Pharmaceuticals - a private pharmaceutical company focused on the development of anti-inflammatory products for life threatening cardiovascular and pulmonary diseases. Previously' he was Founder, President and CEO of Peninsula Pharmaceuticals where he negotiated both of Peninsula's anti-infective product agreements with Shionogi & Co.' Ltd. and Takeda Chemical Industries respectively. Peninsula was acquired by Johnson & Johnson in 2005 for $245 million. Previously, Mr. Truex held positions at Versicor (Vicuron), which was acquired by Pfizer for $1.9 billion, and at Eli Lilly. Mr. Truex obtained his M.B.A. in Marketing and Finance from Indiana University and a B.A. Degree in International Economics from the University of Waterloo.

"We are delighted to have Mr. Truex join Eiger's Board as an Independent Director," said David Cory, President and CEO of Eiger. "Paul will bring valuable experience to our corporate strategy and development as we advance both preclinical and clinical programs at Eiger."

"The combination of newly discovered HCV targets along with clinical and preclinical small molecule inhibitors already identified by Eiger make this a very exciting opportunity in the infectious disease space," said Paul Truex. "I'm looking forward to working with the Eiger board and management team to build a successful company."

Eiger BioPharmaceuticals recently announced the acquisition of exclusive license to novel HCV technology discovered in the labs of Stanford scientist and Eiger Founder Dr. Jeffrey Glenn, MD, PhD. This technology targets a specific region found in the HCV protein NS4B, which binds to HCV-RNA and is required for virus replication. Disrupting the function of this protein provides for a new method to treat HCV infection and can help combat drug resistance to HCV polymerase and protease inhibitors.

About Eiger BioPharmaceuticals, Inc.

Eiger is focused on the discovery and development of new antiviral agents against novel targets for the treatment of hepatitis virus infection. Eiger's pipeline includes repurposed clinical stage therapeutic agents as well as NCEs from discovery that exhibit antiviral activity against Hepatitis C, Hepatitis D, and other viruses. Eiger investors include InterWest Partners and Vivo Ventures


SOURCE Eiger BioPharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors
2. Eiger BioPharmaceuticals Raises $7.1 Million A Round
3. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
8. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
9. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
10. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
11. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today ... a patient who developed lymphedema after being treated for breast cancer benefitted from an ... paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... NEWPORT BEACH, Calif. , June 23, 2016 /PRNewswire/ ... offering new biological discoveries to the medical community, has ... and co-founder Matthew Nunez . "We ... provide us with the capital we need to meet ... funding will essentially provide us the runway to complete ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... regulatory and technical consulting, provides a free webinar on Performing Quality ... 13, 2016 at 12pm CT at no charge. , Incomplete investigations are still ...
Breaking Biology Technology:
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
Breaking Biology News(10 mins):